Navigation Links
Cardium Reports on Presentation at American Heart Association Meeting Relating to Gene Delivery to the Heart and Generx Clinical Development
Date:11/15/2010

lferminogene tadenovec, Ad5FGF-4) is a DNA-based angiogenic growth factor therapeutic product candidate representing a new class of cardiovascular biologics as a treatment for patients with advanced coronary artery disease.  Generx is designed to stimulate and promote the growth of collateral vessels to enhance myocardial blood flow (perfusion) following a one-time intracoronary administration from a standard cardiac infusion catheter in patients who have insufficient blood flow due to atherosclerotic plaque build-up in the coronary arteries.  Generx has progressed through four randomized, placebo controlled clinical studies at over 100 medical centers in the United States and Western Europe that have enrolled over 650 patients.

In June 2010, Cardium announced that it had entered into a Master Services Agreement with bioRASI, an international contract research organization, to assist in the conduct of a late-stage clinical study (ASPIRE) designed to support regulatory approval and commercialization activities for Generx in Russia and affiliated jurisdictions, as well as in other newly industrializing markets.  The Generx clinical study will be conducted at three leading medical centers in Moscow and will be a randomized, controlled, parallel-group, multi-center study to evaluate the safety and efficacy of Generx using SPECT imaging of myocardial blood flow in patients with stable angina pectoris.  The primary endpoint will be the change in reversible perfusion defect size as measured by SPECT imaging, which is directly analogous to that successfully used in a Phase 2a clinical study of Generx in the United States.  

Positive results from the prior Phase 2a clinical study (Grines et al., J Am Coll Cardiol 2003; 42:1339-47) showed that Generx improved myocardial blood flow in the ischemic region of the hearts of men and women following a single intracoronary infusion as measured by the objective efficacy endpoint o
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Aware, Inc. Reports Third Quarter 2010 Financial Results
2. Smithsonian reports regional sea temperature rise and coral bleaching event in Western Caribbean
3. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
4. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
5. GEN reports on the greening of the life sciences
6. Aware, Inc. Reports Second Quarter 2010 Financial Results
7. GEN reports on rediscovered technology to bolster proteomics research
8. BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results
9. International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit
10. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
11. New climate change reports underscore need for action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
(Date:4/17/2014)... and fragmentation of forests in the Amazon help ... contributing to rapid and widespread forest loss during ... The findings show that forests in the Amazon ... coupled with forest fires lead to large-scale loss ... Balch, assistant professor of geography, Penn State. , ...
(Date:4/17/2014)... have detected new early-warning signs of the potential loss ... far-reaching implications for the diagnosis and treatment of diabetic ... Americans. , "We had not expected to see such ... said Ann Elsner, professor and associate dean in the ... study. "We set out to study the early signs, ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... NEW YORK, Dec. 14, 2010 Reportlinker.com announces that ... catalogue: Global Biochip Markets: Microarrays and ... INTRODUCTION  STUDY GOALS ... study was to determine the status of current and ...
... Sustainability is the theme for the 65th Annual International ... in Portland June 19 to 21. Hundreds of scientists, ... non-profit groups, and private industry will gather to discuss ... information about innovations in the field., "The theme of ...
... (June 10, 2011) The Academy of Natural Sciences ... FMC Corporation to help Philadelphia public middle school students and ... career opportunities in the sciences. The $25,000 grant from the ... Academy for some 800 6th through 8th graders and their ...
Cached Biology News:Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 5Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 6Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 7Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 8Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 9Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 10Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 11Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 12Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 13Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 14Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 15Grant funds science career days for Philadelphia public school students 2
(Date:1/15/2014)... Calif. (PRWEB) January 15, 2014 Cynvenio, ... and management through the genomic analysis of tumor cells ... Therapy Finder™, a web-based cancer decision support application powered ... option with Cynvenio’s ClearID™ genomic test, Therapy Finder will ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Nov. 3, 2010 Sangamo BioSciences, Inc. ... has been awarded a total of $978,000 in grants ... Discovery Project Program. Under the recently ... section 48D of the Internal Revenue Code, cash grants ...
... ... ... var shortURL ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
... Mass., Nov. 2, 2010 Repligen Corporation (Nasdaq: ... quarter of fiscal year 2011, ended September 30, 2010. ... to total revenue of $5,421,000 for the second quarter ... 35%.  Bioprocessing product revenue for the second quarter was ...
Cached Biology Technology:Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs 2Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs 3IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 2IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 3IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 4IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 5IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 6IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 7IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 8IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 9Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 2Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 3Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 4Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 5Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 6Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 7
... CC1041 is a recombinant 177 amino ... Gly265 of mature human MT1-MMP. Produced ... of MT1-MMP purified from E. coli periplasm. ... catalytic domain is = 140 mU/mg, where ...
... mM sodium phosphate buffer, pH 6.5. Cathepsin ... a major lysosomal aspartyl protease in mammalian ... Overexpression of cathepsin D in human breast ... relapse and metastasis. Cathepsin D degrades extracellular ...
... in Refrigerated Vapor Trap Models RVT100, RVT400, ... Models UVS400, UVS400A and UVS800DDA., A non-corrosive, ... use for temperatures ranging from -105 to ... stability and does not evaporate. Far superior ...
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
Biology Products: